These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37701329)

  • 1. Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre.
    Yeo M; Rehsi P; Dorman M; Grunewald S; Baruteau J; Chakrapani A; Footitt E; Prunty H; McSweeney M
    JIMD Rep; 2023 Sep; 64(5):317-326. PubMed ID: 37701329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct replacement of oral sodium benzoate with glycerol phenylbutyrate in children with urea cycle disorders.
    Yeo M; Rehsi P; Dorman M; Grunewald S; Baruteau J; Chakrapani A; Footitt E; Prunty H; McSweeney M
    JIMD Rep; 2022 Mar; 63(2):137-145. PubMed ID: 35281661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
    Smith W; Diaz GA; Lichter-Konecki U; Berry SA; Harding CO; McCandless SE; LeMons C; Mauney J; Dickinson K; Coakley DF; Moors T; Mokhtarani M; Scharschmidt BF; Lee B
    J Pediatr; 2013 Jun; 162(6):1228-34, 1234.e1. PubMed ID: 23324524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
    Berry SA; Lichter-Konecki U; Diaz GA; McCandless SE; Rhead W; Smith W; Lemons C; Nagamani SC; Coakley DF; Mokhtarani M; Scharschmidt BF; Lee B
    Mol Genet Metab; 2014 May; 112(1):17-24. PubMed ID: 24630270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to Glycerol Phenylbutyrate in 48 Patients with Urea Cycle Disorders: Clinical Experience in Spain.
    Martín-Hernández E; Quijada-Fraile P; Correcher P; Meavilla S; Sánchez-Pintos P; de Las Heras Montero J; Blasco-Alonso J; Dougherty L; Marquez A; Peña-Quintana L; Cañedo E; García-Jimenez MC; Moreno Lozano PJ; Murray Hurtado M; Camprodon Gómez M; Barrio-Carreras D; de Los Santos M; Del Toro M; Couce ML; Vitoria Miñana I; Morales Conejo M; Bellusci M
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
    Longo N; Diaz GA; Lichter-Konecki U; Schulze A; Inbar-Feigenberg M; Conway RL; Bannick AA; McCandless SE; Zori R; Hainline B; Ah Mew N; Canavan C; Vescio T; Kok T; Porter MH; Berry SA
    Mol Genet Metab; 2021 Jan; 132(1):19-26. PubMed ID: 33388234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
    Berry SA; Longo N; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Robinson B; Vockley J
    Mol Genet Metab; 2017 Nov; 122(3):46-53. PubMed ID: 28916119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
    Lichter-Konecki U; Diaz GA; Merritt JL; Feigenbaum A; Jomphe C; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt B; Rhead W
    Mol Genet Metab; 2011 Aug; 103(4):323-9. PubMed ID: 21612962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
    Lee B; Rhead W; Diaz GA; Scharschmidt BF; Mian A; Shchelochkov O; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Gargosky S; Mokhtarani M; Berry SA
    Mol Genet Metab; 2010 Jul; 100(3):221-8. PubMed ID: 20382058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition to glycerol phenylbutyrate for the management of urea cycle disorders: clinical experiences.
    Sacchini M; Procopio E; Pochiero F; Scaturro G; Daniotti M; Donati MA
    Eur Rev Med Pharmacol Sci; 2023 Nov; 27(22):11131-11142. PubMed ID: 38039045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
    Berry SA; Vockley J; Vinks AA; Dong M; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Perdok R; Robinson B; Holt RJ; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):251-257. PubMed ID: 30217721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
    Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients.
    Diaz GA; Schulze A; Longo N; Rhead W; Feigenbaum A; Wong D; Merritt JL; Berquist W; Gallagher RC; Bartholomew D; McCandless SE; Smith WE; Harding CO; Zori R; Lichter-Konecki U; Vockley J; Canavan C; Vescio T; Holt RJ; Berry SA
    Mol Genet Metab; 2019 Aug; 127(4):336-345. PubMed ID: 31326288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe loss of appetite and refusal to eat as severe side effect of glycerol phenylbutyrate.
    Grünert SC; Schumann A; Spiekerkoetter U
    JIMD Rep; 2022 Nov; 63(6):521-523. PubMed ID: 36341170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycerol phenylbutyrate for the chronic management of urea cycle disorders.
    Oishi K; Diaz GA
    Expert Rev Endocrinol Metab; 2014 Sep; 9(5):427-434. PubMed ID: 30736206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of phenylbutyrate metabolites by UPLC-MS/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels.
    Jiang Y; Almannai M; Sutton VR; Sun Q; Elsea SH
    Mol Genet Metab; 2017 Nov; 122(3):39-45. PubMed ID: 28888854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
    Nagamani SC; Diaz GA; Rhead W; Berry SA; Le Mons C; Lichter-Konecki U; Bartley J; Feigenbaum A; Schulze A; Longo N; Berquist W; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Kronn D; Zori R; Cederbaum S; Merritt JL; Wong D; Coakley DF; Scharschmidt BF; Dickinson K; Marino M; Lee BH; Mokhtarani M
    Mol Genet Metab; 2015; 116(1-2):29-34. PubMed ID: 26296711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder: a qualitative study.
    Yeowell G; Burns DS; Fatoye F
    J Patient Rep Outcomes; 2021 Oct; 5(1):110. PubMed ID: 34694515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
    McGuire BM; Zupanets IA; Lowe ME; Xiao X; Syplyviy VA; Monteleone J; Gargosky S; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt BF
    Hepatology; 2010 Jun; 51(6):2077-85. PubMed ID: 20512995
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.